![]() Some of the issues in the Innovent case were not specific to Chinese companies. Earlier this year, FDA rejected the application of China-developed Sintilimab (PD-1 mAb) by Innovent. #Lin wood fireside chat driversThe panelists had inspiring discussion on how the new drivers of U.S.-China collaborations affect partnering strategy and the ways forward, and how both sides can mutually benefit. Wendy Pan: JD, PhD, Partner, Goodwin Procter LLP Patricia Keegan: MD, CMO, TopAlliance Biosciences Inc.ĭavid Shen: JD, PhD, Senior Counsel, Johnson & Johnson Lihua Zheng: JD, PhD, Co-founder & Chief Business Officer, AnHeart Therapeutics Joshua Berlin, Head of Business Development, BioCentury Inc. Jack Wu, PhD, MBA, Head, Global Business Development, Search & Evaluation, Antengene Topic: “Globalization through cross-border partnerships” From left to right: Lihua Zheng, Patricia Keegan, David Shen, and Wendy Pan Panel of Fireside Chat I “Globalization through cross-border partnerships”. The 2022 deal value will still likely be much higher than the pre-pandemic level though less than 20.There are some positive signs in China healthcare VC investment where the quarterly deal number of seed + A rounds increased markedly in 1Q22 (from 18 deals in 4Q2021 to 45 in 1Q2022).Speaker: Yanhong Lin, MBA, Founder and Managing Partner at CTIC Capital ![]() ![]() Topic: “Cross-Border Fund Raising & Business Development: Opportunities and Challenges” ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |